Glucagonoma and Dacarbazine

DUNCAN, LEWIS A.

doi:10.7326/0003-4819-97-6-930_1

Cited by 7 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Munn and Prinz4 reported the beneficial effects of treatment with dimethyltriazenoimidazole carboxamide (DTIC) in two patients. However, lack of response to DTIC and relapse of glucagonoma syndrome after treatment with DTIC have also been reported 19,20…”

Section: Discussionmentioning

confidence: 99%

Curative resection for malignant glucagonoma

Ishimura

Yachida

Okano

et al. 1996

J Hep Bil Pancr Surg

View full text Add to dashboard Cite

Glucagonoma is a rare endocrine tumor of the pancreas. We report curative resection for malignant glucagonoma in 60-year-old Japanese man admitted to our department because of hyperglycemia and a pancreatic tumor (detected at another institution). On admission, his serum glucagon level was 580pg/ml. Computed tomography (CT) showed a tumor measuring approximately 2cm in diameter, in the head of the pancreas. Angiography revealed a hypervascular lesion fed from the gastro-duodenal artery. Endoscopic retrograde cholangiopancreatography (ERCP), revealed a stenosis of the pancreatic duct in the head of the pancreas and dilation of the caudal side, with indications that the tumor had invaded the pancreatic duct. The tumor was diagnosed as a glucagonoma in the head of the pancreas. Pancreaticoduodenectomy was successfully performed. In the resected specimen, the tumor, which was well defined within the peripheral parenchyma of the pancreas, measured 3.3 • 2.5 • 2.0cm. The clinico-pathological stage of the tumor on pTNM classification was Stage III (pTlb, pN1, pM0). Although the prognosis for malignant glucagonoma is very poor because distant metastasis is frequently present when the tumor is diagnosed, and because of the hormonal effects of the tumor, the patient was well when discharged, without any complications, and no recurrence has been detected in the 6 years since the operation.

show abstract

Section: Discussionmentioning

confidence: 99%

Curative resection for malignant glucagonoma

Ishimura

Yachida

Okano

et al. 1996

J Hep Bil Pancr Surg

View full text Add to dashboard Cite

show abstract

“…Different regimens of dacarbazine have been used for more than three decades. Early reports included clinical and morphological responses in patients with glucagonoma syndrome [ 4 , 5 ]. The largest monotherapy study so far comprised 50 patients with progressive pNET treated with 850 mg/m2 dacarbazine every 4 weeks.…”

Section: Introductionmentioning

confidence: 99%

Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors

Mueller

Krug²,

Majumder

et al. 2016

BMC Cancer

View full text Add to dashboard Cite

BackgroundStreptozocin (STZ) based chemotherapy is recommended for patients with metastatic pancreatic neuroendocrine tumors (pNET). Temozolomide as mono- or combination therapy has been suggested to be a promising alternative. However, the treatment is costly and not approved for the treatment of pNETs. Dacarbazine (DTIC) shares the active metabolite with temozolomide and is broadly available at a low cost. The aim of this study was a retrospective evaluation of the efficacy and tolerability of a lower dose DTIC-regimen in patients with progressive advanced NETs.MethodsWe retrospectively analyzed 75 patients with NETs predominantly of pancreatic origin treated at our center between 1998 and 2013. 650 mg/m2 of DTIC were administered intravenously over 60 min every 4 weeks. Morphological response was assessed according to RECIST1.1 criteria. The median progression free survival (PFS) was calculated using Kaplan-Meier and Cox regression methods, respectively. Univariate analyses of possible prognostic markers were performed.ResultsThe objective response rate (ORR) was 27 % for the entire cohort and 32 % in 50 pNET patients, respectively. Stable disease (SD) was documented in 29 patients (39 %). Median PFS (mPFS) in patients receiving DTIC was 7 months (3.9–10; 95 % confidence interval). Radiological and biochemical response were the only significant prognostic markers for longer PFS in univariate analysis. Treatment was well tolerated. Nausea was the most common side effect (31 %), only one case (1.3 %) of grade 3 toxicity (vomiting) occurred.ConclusionLow dose DTIC chemotherapy is an effective and well-tolerated treatment option in patients with progressive well differentiated neuroendocrine neoplasms, especially of pancreatic origin.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-2642-1) contains supplementary material, which is available to authorized users.

show abstract

Dithiocarbamic Acid and Derivatives

Schubart

2000

Ullmann's Encyclopedia of Industrial Chemistry

View full text Add to dashboard Cite

The article contains sections titled: 1. Introduction 2. Physical and Chemical Properties 3. Manufacture of Dithiocarbamate Salts 4. Transformation Products 4.1. Thiuram Sulfides 4.1.1. Thiuram Disulfides 4.1.2. Thiuram Monosulfides 4.1.3. Thiuram Trisulfides and Tetrasulfides 4.2. Thiocarbamoylsulfenamides 4.3. Thiocarbamoyl Chlorides 4.4. Dithiocarbamic Acid Esters 4.5. Heterocyclic Compounds 4.6. Other Derivatives 4.6.1. Dithiolanylium Salts 4.6.2. Alkylthioformimidic Chlorides 4.6.3. Isothiocyanates, Isocyanates, and Thioureas 4.7. Photolysis of Dithiocarbamates 5. Uses 5.1. Vulcanization Accelerators 5.2. Pesticides 5.3. Medical Applications 5.4. Radioprotective Agents 5.5. Imaging Technology 5.6. Other Uses 6. Toxicology and Occupational Health

show abstract

Glucagonoma and Dacarbazine

Cited by 7 publications

References 1 publication

Curative resection for malignant glucagonoma

Curative resection for malignant glucagonoma

Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors

Dithiocarbamic Acid and Derivatives

Contact Info

Product

Resources

About